HERENTALS, Belgium, Dec. 8 /PRNewswire/ -- Kemin Pharma announces the formation of a collaborative molecule-screening program with the US Army Medical Research Institute for Infectious Diseases (USAMRIID). Under the terms of the agreement, signed in October 2003, USAMRIID will screen Kemin Pharma's library of carbohydrate-based small molecules for effectiveness against SARS and smallpox.
"Kemin Pharma has developed a library of proprietary, carbohydrate-based, bicyclic, small molecules," says Dr. Benedikt Sas, general manager of the company. "Our internal screenings have identified several novel, highly active and selective lead molecules effective against cytomegalorvirus (CMV), hepatitis C virus (HCV) and herpes simplex virus (HSV). By collaborating with USAMRIID, our new molecules will be screened for two additional diseases that also have significant worldwide implications," he added.
Located in Fort Detrick, Maryland, the USAMRIID is the Department of Defense's lead laboratory for medical aspects of biological warfare defense. Although its primary mission is to protect members of the United States military, the research programs it conducts have applications that benefit society as a whole. USAMRIID investigates naturally occurring infectious diseases that require special containment. Its investigators actively contribute to advances in scientific knowledge and collaborate with the Centers for Disease Control and Prevention and the World Health Organization.
Kemin Pharma was established in January 2001, as wholly owned, independent subsidiary of Kemin Industries, Inc. Its mission is to develop new, unique, antimicrobial compounds effective against bacteria, viruses and fungi, as well as protozoa, which present a serious, unmet medical challenge throughout the world. Through a proprietary pre-screening program, Kemin Pharma has been focusing its screening efforts on compounds that are likely to have a higher success rate. This strategy has proven to very successful. Since its formation nearly three years ago, Kemin researchers have isolated and are currently conducting preclinical trials on six compounds and are conducting Phase II trials on another compound. Kemin Industries, Inc. has a 40-year history of identifying unique compounds, developing them to meet stringent regulatory requirements and introducing them to the human and livestock markets.
CONTACT: Dr. Benedikt Sas, General Manager of Kemin Pharma,+32-14-36-91-60, or Benedikt.Sas@keminpharma.be